We are live on ! Find out more
ONSIZ

Oncobiologics, Inc. Series B Warrant

Delisted

ONSIZ was delisted on the 16th of May, 2018.

0 hedge funds and large institutions have $0 invested in Oncobiologics, Inc. Series B Warrant in 2018 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 90 (-9)

100% less capital invested

Capital invested by funds: $43K → $0 (-$43K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 9

Holders
Holders Change
-9
Holders Change %
-100%
% of All Funds
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
9
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
CAM
1
Cormorant Asset Management
Massachusetts
-$18K -416,666 Closed
ACA
2
Avoro Capital Advisors
New York
-$12K -233,333 Closed
MWNA
3
Marshall Wace North America
New York
-$6K -125,100 Closed
PC
4
PointState Capital
New York
-$4K -100,000 Closed
Millennium Management
5
Millennium Management
New York
-$1K -29,658 Closed
MIM
6
Monashee Investment Management
Massachusetts
-$1K -25,000 Closed
Susquehanna International Group
7
Susquehanna International Group
Pennsylvania
-$1K -15,603 Closed

ONSIZ Hedge Fund Activity: Q2 2018 in Review

0 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Oncobiologics, Inc. Series B Warrant (ONSIZ) for Q2 2018, worth a combined $0 — down 100% from $43K a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of ONSIZ and 0 opened new positions — a net loss of 9 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Cormorant Asset Management, exiting entirely with an estimated $18K sold.

  • 0 institutional investors held Oncobiologics, Inc. Series B Warrant (ONSIZ) as of Q2 2018, down from 9 in Q1 2018.
  • Funds reported $0 of Oncobiologics, Inc. Series B Warrant stock for Q2 2018, down 100% quarter-over-quarter.
  • 0 funds opened new Oncobiologics, Inc. Series B Warrant positions in Q2 2018 and 9 closed out, a net change of -9 holders.
  • The largest Oncobiologics, Inc. Series B Warrant seller in Q2 2018 was Cormorant Asset Management, an estimated $18K sold.

Based on aggregated 13F filings for Q2 2018.